PreveCeutical Medical Inc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stephen van Deventer
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 5428 Marine Drive Vancouver BC Canada V7W 2R2
- IPO Date
- Jan 11, 2017
- Website
- preveceutical.com
- Similar Companies
- Business
- PreveCeutical Medical Inc. PreveCeutical Medical Inc. (CSE: PREV), a health sciences company headquartered in West Vancouver, British Columbia, Canada, and incorporated in British Columbia on October 2, 2015, develops innovative options for preventive and curative therapies utilizing organic and nature-identical products targeting unmet clinical needs in areas such as diabetes and obesity, pain management, neurological disorders, cancer, and inflammation; its core research and development programs encompass the Sol-Gel Program for nose-to-brain delivery of cannabinoids and other agents to treat pain, inflammation, seizures, and neurological conditions; Nature Identical™ peptides under the BSV Peptide Program to address cancer progression and various ailments; non-addictive analgesic peptides as alternatives to opioids like morphine, fentanyl, and oxycodone for moderate to severe pain and inflammatory conditions; and a therapeutic product for concussions or mild traumatic brain injury in athletes, with operations supported by a wholly-owned Australian subsidiary, PreveCeutical (Australia) Pty Ltd., incorporated in Queensland in 2018 to leverage research incentives and partnerships including historical collaborations with the University of Queensland and UniQuest Pty Limited. In recent strategic developments, PreveCeutical completed a significant plan of arrangement effective November 25, 2025, spinning out 12,000,000 common shares of its subsidiary BioGene Therapeutics Inc. to shareholders on a pro rata basis following an intellectual property asset sale valued at USD$1,353,227 in October 2024, enabling BioGene to independently advance the Dual Gene Therapy program for type 2 diabetes and obesity while PreveCeutical retains focus on its remaining preventive health initiatives; the company also maintains patent filings, including an International PCT application for pain management peptides and provisional patents for peptide therapeutics secured through Griffith Hack, alongside board enhancements with experts like Dr. Linnéa Olofsson and Kathleen Rokita to support commercialization efforts.
Company News
PreveCeutical Announces Non-Brokered Private Placement
PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement
PreveCeutical Closes Third Tranche of Non-Brokered Private Placement
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
PreveCeutical Announces Extension of Non-Brokered Private Placement
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
PreveCeutical Announces Non-Brokered Private Placement
PreveCeutical Adopts Semi-Annual Financial Reporting
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement
CSE Bulletin: Notice of Distribution and Reclassification - PreveCeutical Medical Inc. (PREV)
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.